nodes	percent_of_prediction	percent_of_DWPC	metapath
Gliclazide—VEGFA—head and neck cancer	0.832	1	CbGaD
Gliclazide—ALB—Fluorouracil—head and neck cancer	0.0137	0.65	CbGbCtD
Gliclazide—CYP2C9—Fluorouracil—head and neck cancer	0.00737	0.35	CbGbCtD
Gliclazide—Gastric irritation—Hydroxyurea—head and neck cancer	0.00245	0.0256	CcSEcCtD
Gliclazide—Epigastric discomfort—Hydroxyurea—head and neck cancer	0.00181	0.0189	CcSEcCtD
Gliclazide—Cerebrovascular disorder—Fluorouracil—head and neck cancer	0.00153	0.016	CcSEcCtD
Gliclazide—Reaction gastrointestinal—Docetaxel—head and neck cancer	0.00148	0.0155	CcSEcCtD
Gliclazide—Digestion impaired—Hydroxyurea—head and neck cancer	0.00142	0.0149	CcSEcCtD
Gliclazide—Numbness—Vinblastine—head and neck cancer	0.00126	0.0131	CcSEcCtD
Gliclazide—Skin ulcer—Hydroxyurea—head and neck cancer	0.00122	0.0128	CcSEcCtD
Gliclazide—Sensory loss—Vinblastine—head and neck cancer	0.0012	0.0126	CcSEcCtD
Gliclazide—Lacrimal disorder—Docetaxel—head and neck cancer	0.0011	0.0116	CcSEcCtD
Gliclazide—Bone pain—Vinblastine—head and neck cancer	0.00109	0.0114	CcSEcCtD
Gliclazide—Nail disorder—Fluorouracil—head and neck cancer	0.00106	0.011	CcSEcCtD
Gliclazide—Duodenal ulcer—Docetaxel—head and neck cancer	0.00102	0.0107	CcSEcCtD
Gliclazide—Hepatic enzyme increased—Hydroxyurea—head and neck cancer	0.00101	0.0105	CcSEcCtD
Gliclazide—Heartburn—Fluorouracil—head and neck cancer	0.000994	0.0104	CcSEcCtD
Gliclazide—Neoplasm—Vinblastine—head and neck cancer	0.000943	0.00986	CcSEcCtD
Gliclazide—Blood urea increased—Hydroxyurea—head and neck cancer	0.000898	0.00939	CcSEcCtD
Gliclazide—Rash maculo-papular—Hydroxyurea—head and neck cancer	0.000864	0.00904	CcSEcCtD
Gliclazide—Neoplasm—Hydroxyurea—head and neck cancer	0.00086	0.00899	CcSEcCtD
Gliclazide—Deafness—Vinblastine—head and neck cancer	0.000846	0.00885	CcSEcCtD
Gliclazide—Haemorrhoids—Docetaxel—head and neck cancer	0.00084	0.00878	CcSEcCtD
Gliclazide—Numbness—Fluorouracil—head and neck cancer	0.000826	0.00863	CcSEcCtD
Gliclazide—Speech disorder—Fluorouracil—head and neck cancer	0.000796	0.00832	CcSEcCtD
Gliclazide—Sensory loss—Fluorouracil—head and neck cancer	0.00079	0.00826	CcSEcCtD
Gliclazide—Cerebrovascular accident—Vinblastine—head and neck cancer	0.000772	0.00807	CcSEcCtD
Gliclazide—Hepatic failure—Hydroxyurea—head and neck cancer	0.000768	0.00803	CcSEcCtD
Gliclazide—Nail disorder—Docetaxel—head and neck cancer	0.000762	0.00796	CcSEcCtD
Gliclazide—Renal failure acute—Hydroxyurea—head and neck cancer	0.000748	0.00782	CcSEcCtD
Gliclazide—Heartburn—Docetaxel—head and neck cancer	0.000718	0.0075	CcSEcCtD
Gliclazide—Neuralgia—Docetaxel—head and neck cancer	0.000711	0.00743	CcSEcCtD
Gliclazide—Angina pectoris—Vinblastine—head and neck cancer	0.000637	0.00666	CcSEcCtD
Gliclazide—Otitis media—Docetaxel—head and neck cancer	0.000635	0.00663	CcSEcCtD
Gliclazide—Oesophagitis—Fluorouracil—head and neck cancer	0.000625	0.00654	CcSEcCtD
Gliclazide—Coma—Fluorouracil—head and neck cancer	0.000625	0.00654	CcSEcCtD
Gliclazide—Rash maculo-papular—Fluorouracil—head and neck cancer	0.000622	0.0065	CcSEcCtD
Gliclazide—Pancytopenia—Vinblastine—head and neck cancer	0.000621	0.00649	CcSEcCtD
Gliclazide—Depression—Vinblastine—head and neck cancer	0.000582	0.00608	CcSEcCtD
Gliclazide—Acute coronary syndrome—Vinblastine—head and neck cancer	0.000575	0.00601	CcSEcCtD
Gliclazide—Thrombophlebitis—Fluorouracil—head and neck cancer	0.000574	0.006	CcSEcCtD
Gliclazide—Neuropathy peripheral—Vinblastine—head and neck cancer	0.000572	0.00598	CcSEcCtD
Gliclazide—Myocardial infarction—Vinblastine—head and neck cancer	0.000572	0.00598	CcSEcCtD
Gliclazide—Pancytopenia—Hydroxyurea—head and neck cancer	0.000567	0.00592	CcSEcCtD
Gliclazide—Photosensitivity—Fluorouracil—head and neck cancer	0.000566	0.00592	CcSEcCtD
Gliclazide—Agranulocytosis—Vinblastine—head and neck cancer	0.000544	0.00569	CcSEcCtD
Gliclazide—Weight increased—Hydroxyurea—head and neck cancer	0.000543	0.00568	CcSEcCtD
Gliclazide—Drowsiness—Hydroxyurea—head and neck cancer	0.000532	0.00556	CcSEcCtD
Gliclazide—Neuropathy peripheral—Hydroxyurea—head and neck cancer	0.000521	0.00545	CcSEcCtD
Gliclazide—Hypoaesthesia—Vinblastine—head and neck cancer	0.000521	0.00545	CcSEcCtD
Gliclazide—Pharyngitis—Vinblastine—head and neck cancer	0.00052	0.00543	CcSEcCtD
Gliclazide—Hearing impaired—Docetaxel—head and neck cancer	0.000519	0.00543	CcSEcCtD
Gliclazide—Bone pain—Docetaxel—head and neck cancer	0.000516	0.00539	CcSEcCtD
Gliclazide—Cardiac failure—Fluorouracil—head and neck cancer	0.000509	0.00532	CcSEcCtD
Gliclazide—Hepatobiliary disease—Hydroxyurea—head and neck cancer	0.000503	0.00526	CcSEcCtD
Gliclazide—Osteoarthritis—Fluorouracil—head and neck cancer	0.000497	0.00519	CcSEcCtD
Gliclazide—Gastrointestinal haemorrhage—Fluorouracil—head and neck cancer	0.000497	0.00519	CcSEcCtD
Gliclazide—Blood pressure increased—Docetaxel—head and neck cancer	0.000494	0.00516	CcSEcCtD
Gliclazide—Colitis—Docetaxel—head and neck cancer	0.000474	0.00496	CcSEcCtD
Gliclazide—Neuropathy—Docetaxel—head and neck cancer	0.000464	0.00485	CcSEcCtD
Gliclazide—Dry skin—Fluorouracil—head and neck cancer	0.000455	0.00476	CcSEcCtD
Gliclazide—Oesophagitis—Docetaxel—head and neck cancer	0.000451	0.00472	CcSEcCtD
Gliclazide—Neoplasm—Docetaxel—head and neck cancer	0.000447	0.00467	CcSEcCtD
Gliclazide—Chills—Hydroxyurea—head and neck cancer	0.000428	0.00448	CcSEcCtD
Gliclazide—Ill-defined disorder—Vinblastine—head and neck cancer	0.000423	0.00442	CcSEcCtD
Gliclazide—Anaemia—Vinblastine—head and neck cancer	0.000421	0.0044	CcSEcCtD
Gliclazide—Angina pectoris—Fluorouracil—head and neck cancer	0.000418	0.00437	CcSEcCtD
Gliclazide—Erythema—Hydroxyurea—head and neck cancer	0.000416	0.00435	CcSEcCtD
Gliclazide—Thrombophlebitis—Docetaxel—head and neck cancer	0.000414	0.00433	CcSEcCtD
Gliclazide—Blood alkaline phosphatase increased—Docetaxel—head and neck cancer	0.000412	0.00431	CcSEcCtD
Gliclazide—Malaise—Vinblastine—head and neck cancer	0.000411	0.0043	CcSEcCtD
Gliclazide—Leukopenia—Vinblastine—head and neck cancer	0.000408	0.00427	CcSEcCtD
Gliclazide—Pancytopenia—Fluorouracil—head and neck cancer	0.000408	0.00426	CcSEcCtD
Gliclazide—Deafness—Docetaxel—head and neck cancer	0.000401	0.00419	CcSEcCtD
Gliclazide—Upper respiratory tract infection—Fluorouracil—head and neck cancer	0.000399	0.00417	CcSEcCtD
Gliclazide—Hepatic failure—Docetaxel—head and neck cancer	0.000399	0.00417	CcSEcCtD
Gliclazide—Convulsion—Vinblastine—head and neck cancer	0.000395	0.00413	CcSEcCtD
Gliclazide—Hypertension—Vinblastine—head and neck cancer	0.000394	0.00411	CcSEcCtD
Gliclazide—Photosensitivity reaction—Fluorouracil—head and neck cancer	0.000392	0.0041	CcSEcCtD
Gliclazide—Ill-defined disorder—Hydroxyurea—head and neck cancer	0.000386	0.00403	CcSEcCtD
Gliclazide—Pneumonia—Fluorouracil—head and neck cancer	0.000385	0.00403	CcSEcCtD
Gliclazide—Anaemia—Hydroxyurea—head and neck cancer	0.000384	0.00402	CcSEcCtD
Gliclazide—Discomfort—Vinblastine—head and neck cancer	0.000383	0.00401	CcSEcCtD
Gliclazide—Visual disturbance—Docetaxel—head and neck cancer	0.000378	0.00396	CcSEcCtD
Gliclazide—Acute coronary syndrome—Fluorouracil—head and neck cancer	0.000377	0.00395	CcSEcCtD
Gliclazide—Renal impairment—Docetaxel—head and neck cancer	0.000377	0.00394	CcSEcCtD
Gliclazide—Myocardial infarction—Fluorouracil—head and neck cancer	0.000375	0.00392	CcSEcCtD
Gliclazide—Neuropathy peripheral—Fluorouracil—head and neck cancer	0.000375	0.00392	CcSEcCtD
Gliclazide—Malaise—Hydroxyurea—head and neck cancer	0.000375	0.00392	CcSEcCtD
Gliclazide—Conjunctivitis—Fluorouracil—head and neck cancer	0.000372	0.00389	CcSEcCtD
Gliclazide—Urinary tract infection—Fluorouracil—head and neck cancer	0.000372	0.00389	CcSEcCtD
Gliclazide—Leukopenia—Hydroxyurea—head and neck cancer	0.000372	0.00389	CcSEcCtD
Gliclazide—Cardiac failure—Docetaxel—head and neck cancer	0.000367	0.00384	CcSEcCtD
Gliclazide—Thrombocytopenia—Vinblastine—head and neck cancer	0.000364	0.00381	CcSEcCtD
Gliclazide—Epistaxis—Fluorouracil—head and neck cancer	0.000361	0.00378	CcSEcCtD
Gliclazide—Convulsion—Hydroxyurea—head and neck cancer	0.00036	0.00377	CcSEcCtD
Gliclazide—Hyponatraemia—Docetaxel—head and neck cancer	0.00036	0.00376	CcSEcCtD
Gliclazide—Sinusitis—Fluorouracil—head and neck cancer	0.000359	0.00376	CcSEcCtD
Gliclazide—Pain in extremity—Docetaxel—head and neck cancer	0.000359	0.00375	CcSEcCtD
Gliclazide—Gastrointestinal haemorrhage—Docetaxel—head and neck cancer	0.000359	0.00375	CcSEcCtD
Gliclazide—Agranulocytosis—Fluorouracil—head and neck cancer	0.000357	0.00374	CcSEcCtD
Gliclazide—Unspecified disorder of skin and subcutaneous tissue—Hydroxyurea—head and neck cancer	0.000351	0.00367	CcSEcCtD
Gliclazide—Discomfort—Hydroxyurea—head and neck cancer	0.00035	0.00366	CcSEcCtD
Gliclazide—Rhinitis—Fluorouracil—head and neck cancer	0.000345	0.0036	CcSEcCtD
Gliclazide—Hypoaesthesia—Fluorouracil—head and neck cancer	0.000342	0.00358	CcSEcCtD
Gliclazide—Pharyngitis—Fluorouracil—head and neck cancer	0.000341	0.00357	CcSEcCtD
Gliclazide—Infection—Hydroxyurea—head and neck cancer	0.000337	0.00352	CcSEcCtD
Gliclazide—Paraesthesia—Vinblastine—head and neck cancer	0.000334	0.00349	CcSEcCtD
Gliclazide—Nervous system disorder—Hydroxyurea—head and neck cancer	0.000333	0.00348	CcSEcCtD
Gliclazide—Thrombocytopenia—Hydroxyurea—head and neck cancer	0.000332	0.00347	CcSEcCtD
Gliclazide—Skin disorder—Hydroxyurea—head and neck cancer	0.00033	0.00345	CcSEcCtD
Gliclazide—Dry skin—Docetaxel—head and neck cancer	0.000329	0.00344	CcSEcCtD
Gliclazide—Toxic epidermal necrolysis—Docetaxel—head and neck cancer	0.000323	0.00338	CcSEcCtD
Gliclazide—Constipation—Vinblastine—head and neck cancer	0.000318	0.00333	CcSEcCtD
Gliclazide—Pain—Vinblastine—head and neck cancer	0.000318	0.00333	CcSEcCtD
Gliclazide—CYP2C19—Melatonin metabolism and effects—CYP1A1—head and neck cancer	0.000309	0.00608	CbGpPWpGaD
Gliclazide—VEGFA—SHP2 signaling—IL2—head and neck cancer	0.000309	0.00607	CbGpPWpGaD
Gliclazide—Arrhythmia—Fluorouracil—head and neck cancer	0.000307	0.00321	CcSEcCtD
Gliclazide—Feeling abnormal—Vinblastine—head and neck cancer	0.000307	0.0032	CcSEcCtD
Gliclazide—Gastrointestinal pain—Vinblastine—head and neck cancer	0.000304	0.00318	CcSEcCtD
Gliclazide—Dyspnoea—Hydroxyurea—head and neck cancer	0.000302	0.00316	CcSEcCtD
Gliclazide—Angina pectoris—Docetaxel—head and neck cancer	0.000302	0.00316	CcSEcCtD
Gliclazide—Somnolence—Hydroxyurea—head and neck cancer	0.000302	0.00315	CcSEcCtD
Gliclazide—Erythema—Fluorouracil—head and neck cancer	0.000299	0.00313	CcSEcCtD
Gliclazide—Dyspepsia—Hydroxyurea—head and neck cancer	0.000299	0.00312	CcSEcCtD
Gliclazide—VEGFA—Heart Development—MAPK1—head and neck cancer	0.000295	0.00579	CbGpPWpGaD
Gliclazide—Pancytopenia—Docetaxel—head and neck cancer	0.000294	0.00308	CcSEcCtD
Gliclazide—Abdominal pain—Vinblastine—head and neck cancer	0.000294	0.00307	CcSEcCtD
Gliclazide—Gastrointestinal disorder—Hydroxyurea—head and neck cancer	0.000293	0.00306	CcSEcCtD
Gliclazide—Fatigue—Hydroxyurea—head and neck cancer	0.000292	0.00306	CcSEcCtD
Gliclazide—VEGFA—VEGFR1 specific signals—AKT1—head and neck cancer	0.000292	0.00573	CbGpPWpGaD
Gliclazide—VEGFA—VEGFR2 mediated cell proliferation—HRAS—head and neck cancer	0.000291	0.00572	CbGpPWpGaD
Gliclazide—Pain—Hydroxyurea—head and neck cancer	0.00029	0.00303	CcSEcCtD
Gliclazide—Constipation—Hydroxyurea—head and neck cancer	0.00029	0.00303	CcSEcCtD
Gliclazide—VEGFA—Aryl Hydrocarbon Receptor—MAPK1—head and neck cancer	0.000284	0.00559	CbGpPWpGaD
Gliclazide—VEGFA—Aryl Hydrocarbon Receptor—EGFR—head and neck cancer	0.000284	0.00559	CbGpPWpGaD
Gliclazide—Weight increased—Docetaxel—head and neck cancer	0.000282	0.00295	CcSEcCtD
Gliclazide—Feeling abnormal—Hydroxyurea—head and neck cancer	0.00028	0.00292	CcSEcCtD
Gliclazide—Pneumonia—Docetaxel—head and neck cancer	0.000278	0.00291	CcSEcCtD
Gliclazide—Anaemia—Fluorouracil—head and neck cancer	0.000277	0.00289	CcSEcCtD
Gliclazide—VEGFA—Signaling events mediated by TCPTP—PIK3CA—head and neck cancer	0.000276	0.00542	CbGpPWpGaD
Gliclazide—Hypersensitivity—Vinblastine—head and neck cancer	0.000274	0.00287	CcSEcCtD
Gliclazide—Stevens-Johnson syndrome—Docetaxel—head and neck cancer	0.000274	0.00286	CcSEcCtD
Gliclazide—Acute coronary syndrome—Docetaxel—head and neck cancer	0.000272	0.00285	CcSEcCtD
Gliclazide—Renal failure—Docetaxel—head and neck cancer	0.000272	0.00284	CcSEcCtD
Gliclazide—Neuropathy peripheral—Docetaxel—head and neck cancer	0.000271	0.00283	CcSEcCtD
Gliclazide—Myocardial infarction—Docetaxel—head and neck cancer	0.000271	0.00283	CcSEcCtD
Gliclazide—Jaundice—Docetaxel—head and neck cancer	0.000269	0.00282	CcSEcCtD
Gliclazide—Conjunctivitis—Docetaxel—head and neck cancer	0.000269	0.00281	CcSEcCtD
Gliclazide—Body temperature increased—Hydroxyurea—head and neck cancer	0.000268	0.0028	CcSEcCtD
Gliclazide—Leukopenia—Fluorouracil—head and neck cancer	0.000268	0.0028	CcSEcCtD
Gliclazide—Asthenia—Vinblastine—head and neck cancer	0.000267	0.00279	CcSEcCtD
Gliclazide—Hepatobiliary disease—Docetaxel—head and neck cancer	0.000261	0.00273	CcSEcCtD
Gliclazide—Epistaxis—Docetaxel—head and neck cancer	0.000261	0.00273	CcSEcCtD
Gliclazide—Convulsion—Fluorouracil—head and neck cancer	0.000259	0.00271	CcSEcCtD
Gliclazide—Agranulocytosis—Docetaxel—head and neck cancer	0.000258	0.0027	CcSEcCtD
Gliclazide—Chest pain—Fluorouracil—head and neck cancer	0.000255	0.00266	CcSEcCtD
Gliclazide—Myalgia—Fluorouracil—head and neck cancer	0.000255	0.00266	CcSEcCtD
Gliclazide—Diarrhoea—Vinblastine—head and neck cancer	0.000255	0.00266	CcSEcCtD
Gliclazide—VEGFA—Developmental Biology—CEBPA—head and neck cancer	0.000254	0.00499	CbGpPWpGaD
Gliclazide—ABCC8—Transmembrane transport of small molecules—ATP7B—head and neck cancer	0.000254	0.00498	CbGpPWpGaD
Gliclazide—Discomfort—Fluorouracil—head and neck cancer	0.000252	0.00263	CcSEcCtD
Gliclazide—Hypersensitivity—Hydroxyurea—head and neck cancer	0.00025	0.00261	CcSEcCtD
Gliclazide—Rhinitis—Docetaxel—head and neck cancer	0.000249	0.0026	CcSEcCtD
Gliclazide—Hepatitis—Docetaxel—head and neck cancer	0.000248	0.00259	CcSEcCtD
Gliclazide—Hypoaesthesia—Docetaxel—head and neck cancer	0.000247	0.00258	CcSEcCtD
Gliclazide—Confusional state—Fluorouracil—head and neck cancer	0.000246	0.00257	CcSEcCtD
Gliclazide—Pharyngitis—Docetaxel—head and neck cancer	0.000246	0.00257	CcSEcCtD
Gliclazide—Dizziness—Vinblastine—head and neck cancer	0.000246	0.00257	CcSEcCtD
Gliclazide—Oedema peripheral—Docetaxel—head and neck cancer	0.000244	0.00255	CcSEcCtD
Gliclazide—Asthenia—Hydroxyurea—head and neck cancer	0.000243	0.00254	CcSEcCtD
Gliclazide—Infection—Fluorouracil—head and neck cancer	0.000243	0.00254	CcSEcCtD
Gliclazide—VEGFA—Allograft Rejection—IL2—head and neck cancer	0.000241	0.00474	CbGpPWpGaD
Gliclazide—Nervous system disorder—Fluorouracil—head and neck cancer	0.000239	0.0025	CcSEcCtD
Gliclazide—Thrombocytopenia—Fluorouracil—head and neck cancer	0.000239	0.0025	CcSEcCtD
Gliclazide—Visual impairment—Docetaxel—head and neck cancer	0.000239	0.0025	CcSEcCtD
Gliclazide—Tachycardia—Fluorouracil—head and neck cancer	0.000238	0.00249	CcSEcCtD
Gliclazide—VEGFA—Oncostatin M Signaling Pathway—STAT3—head and neck cancer	0.000237	0.00466	CbGpPWpGaD
Gliclazide—Vomiting—Vinblastine—head and neck cancer	0.000237	0.00247	CcSEcCtD
Gliclazide—VEGFA—SHP2 signaling—EGFR—head and neck cancer	0.000236	0.00464	CbGpPWpGaD
Gliclazide—Erythema multiforme—Docetaxel—head and neck cancer	0.000235	0.00245	CcSEcCtD
Gliclazide—Headache—Vinblastine—head and neck cancer	0.000233	0.00244	CcSEcCtD
Gliclazide—VEGFA—Integrins in angiogenesis—MAPK3—head and neck cancer	0.000232	0.00457	CbGpPWpGaD
Gliclazide—ALB—Vitamin B12 Metabolism—SOD2—head and neck cancer	0.000232	0.00456	CbGpPWpGaD
Gliclazide—Diarrhoea—Hydroxyurea—head and neck cancer	0.000232	0.00243	CcSEcCtD
Gliclazide—Eye disorder—Docetaxel—head and neck cancer	0.000232	0.00242	CcSEcCtD
Gliclazide—VEGFA—Integrated Pancreatic Cancer Pathway—TYMS—head and neck cancer	0.000231	0.00453	CbGpPWpGaD
Gliclazide—Flushing—Docetaxel—head and neck cancer	0.00023	0.00241	CcSEcCtD
Gliclazide—ABCC8—FOXA2 and FOXA3 transcription factor networks—AKT1—head and neck cancer	0.000229	0.00449	CbGpPWpGaD
Gliclazide—VEGFA—Aryl Hydrocarbon Receptor—HRAS—head and neck cancer	0.000228	0.00449	CbGpPWpGaD
Gliclazide—Hypotension—Fluorouracil—head and neck cancer	0.000228	0.00239	CcSEcCtD
Gliclazide—VEGFA—Oncostatin M Signaling Pathway—MAPK3—head and neck cancer	0.000227	0.00446	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—UROD—head and neck cancer	0.000226	0.00444	CbGpPWpGaD
Gliclazide—Dizziness—Hydroxyurea—head and neck cancer	0.000224	0.00235	CcSEcCtD
Gliclazide—Chills—Docetaxel—head and neck cancer	0.000223	0.00233	CcSEcCtD
Gliclazide—Musculoskeletal discomfort—Fluorouracil—head and neck cancer	0.000222	0.00233	CcSEcCtD
Gliclazide—KCNJ11—FOXA2 and FOXA3 transcription factor networks—AKT1—head and neck cancer	0.000222	0.00436	CbGpPWpGaD
Gliclazide—Arrhythmia—Docetaxel—head and neck cancer	0.000222	0.00232	CcSEcCtD
Gliclazide—VEGFA—Integrins in angiogenesis—MAPK1—head and neck cancer	0.000221	0.00435	CbGpPWpGaD
Gliclazide—Nausea—Vinblastine—head and neck cancer	0.000221	0.00231	CcSEcCtD
Gliclazide—Insomnia—Fluorouracil—head and neck cancer	0.000221	0.00231	CcSEcCtD
Gliclazide—KCNJ11—Metabolism—UROD—head and neck cancer	0.000219	0.00431	CbGpPWpGaD
Gliclazide—Paraesthesia—Fluorouracil—head and neck cancer	0.000219	0.00229	CcSEcCtD
Gliclazide—VEGFA—Signaling events mediated by VEGFR1 and VEGFR2—MAPK3—head and neck cancer	0.000219	0.0043	CbGpPWpGaD
Gliclazide—Dyspnoea—Fluorouracil—head and neck cancer	0.000218	0.00228	CcSEcCtD
Gliclazide—Mental disorder—Docetaxel—head and neck cancer	0.000217	0.00227	CcSEcCtD
Gliclazide—Somnolence—Fluorouracil—head and neck cancer	0.000217	0.00227	CcSEcCtD
Gliclazide—Malnutrition—Docetaxel—head and neck cancer	0.000216	0.00226	CcSEcCtD
Gliclazide—Erythema—Docetaxel—head and neck cancer	0.000216	0.00226	CcSEcCtD
Gliclazide—VEGFA—Oncostatin M Signaling Pathway—MAPK1—head and neck cancer	0.000216	0.00424	CbGpPWpGaD
Gliclazide—Vomiting—Hydroxyurea—head and neck cancer	0.000216	0.00226	CcSEcCtD
Gliclazide—Dyspepsia—Fluorouracil—head and neck cancer	0.000215	0.00225	CcSEcCtD
Gliclazide—Rash—Hydroxyurea—head and neck cancer	0.000214	0.00224	CcSEcCtD
Gliclazide—Dermatitis—Hydroxyurea—head and neck cancer	0.000214	0.00223	CcSEcCtD
Gliclazide—Headache—Hydroxyurea—head and neck cancer	0.000213	0.00222	CcSEcCtD
Gliclazide—Gastrointestinal disorder—Fluorouracil—head and neck cancer	0.000211	0.0022	CcSEcCtD
Gliclazide—Back pain—Docetaxel—head and neck cancer	0.000209	0.00218	CcSEcCtD
Gliclazide—Pain—Fluorouracil—head and neck cancer	0.000209	0.00218	CcSEcCtD
Gliclazide—VEGFA—Signaling events mediated by VEGFR1 and VEGFR2—MAPK1—head and neck cancer	0.000208	0.00409	CbGpPWpGaD
Gliclazide—VEGFA—SHP2 signaling—PIK3CA—head and neck cancer	0.000205	0.00403	CbGpPWpGaD
Gliclazide—CYP2C19—Arachidonic acid metabolism—GPX1—head and neck cancer	0.000202	0.00397	CbGpPWpGaD
Gliclazide—Nausea—Hydroxyurea—head and neck cancer	0.000202	0.00211	CcSEcCtD
Gliclazide—Feeling abnormal—Fluorouracil—head and neck cancer	0.000201	0.0021	CcSEcCtD
Gliclazide—CYP2C19—Arachidonic acid metabolism—CYP1A1—head and neck cancer	0.0002	0.00393	CbGpPWpGaD
Gliclazide—Anaemia—Docetaxel—head and neck cancer	0.0002	0.00209	CcSEcCtD
Gliclazide—Urticaria—Fluorouracil—head and neck cancer	0.000194	0.00203	CcSEcCtD
Gliclazide—Leukopenia—Docetaxel—head and neck cancer	0.000193	0.00202	CcSEcCtD
Gliclazide—Body temperature increased—Fluorouracil—head and neck cancer	0.000193	0.00202	CcSEcCtD
Gliclazide—VEGFA—Integrins in angiogenesis—PIK3CA—head and neck cancer	0.000192	0.00377	CbGpPWpGaD
Gliclazide—Palpitations—Docetaxel—head and neck cancer	0.000191	0.002	CcSEcCtD
Gliclazide—VEGFA—Integrated Breast Cancer Pathway—CASP8—head and neck cancer	0.00019	0.00374	CbGpPWpGaD
Gliclazide—Loss of consciousness—Docetaxel—head and neck cancer	0.00019	0.00198	CcSEcCtD
Gliclazide—VEGFA—SHP2 signaling—HRAS—head and neck cancer	0.00019	0.00373	CbGpPWpGaD
Gliclazide—ALB—Folate Metabolism—SOD2—head and neck cancer	0.000189	0.00371	CbGpPWpGaD
Gliclazide—Cough—Docetaxel—head and neck cancer	0.000188	0.00197	CcSEcCtD
Gliclazide—VEGFA—Integrated Breast Cancer Pathway—CDH1—head and neck cancer	0.000188	0.00369	CbGpPWpGaD
Gliclazide—Convulsion—Docetaxel—head and neck cancer	0.000187	0.00196	CcSEcCtD
Gliclazide—Hypertension—Docetaxel—head and neck cancer	0.000186	0.00195	CcSEcCtD
Gliclazide—CYP2C9—Arachidonic acid metabolism—GPX1—head and neck cancer	0.000184	0.00362	CbGpPWpGaD
Gliclazide—Chest pain—Docetaxel—head and neck cancer	0.000184	0.00192	CcSEcCtD
Gliclazide—Arthralgia—Docetaxel—head and neck cancer	0.000184	0.00192	CcSEcCtD
Gliclazide—Myalgia—Docetaxel—head and neck cancer	0.000184	0.00192	CcSEcCtD
Gliclazide—Unspecified disorder of skin and subcutaneous tissue—Docetaxel—head and neck cancer	0.000183	0.00191	CcSEcCtD
Gliclazide—CYP2C9—Arachidonic acid metabolism—CYP1A1—head and neck cancer	0.000182	0.00358	CbGpPWpGaD
Gliclazide—VEGFA—Oncostatin M Signaling Pathway—TP53—head and neck cancer	0.000181	0.00356	CbGpPWpGaD
Gliclazide—VEGFA—Signaling events mediated by VEGFR1 and VEGFR2—PIK3CA—head and neck cancer	0.000181	0.00355	CbGpPWpGaD
Gliclazide—ALB—Folate Metabolism—GPX1—head and neck cancer	0.00018	0.00354	CbGpPWpGaD
Gliclazide—Hypersensitivity—Fluorouracil—head and neck cancer	0.00018	0.00188	CcSEcCtD
Gliclazide—Dry mouth—Docetaxel—head and neck cancer	0.00018	0.00188	CcSEcCtD
Gliclazide—Confusional state—Docetaxel—head and neck cancer	0.000178	0.00186	CcSEcCtD
Gliclazide—VEGFA—Cellular responses to stress—SOD2—head and neck cancer	0.000177	0.00347	CbGpPWpGaD
Gliclazide—Infection—Docetaxel—head and neck cancer	0.000175	0.00183	CcSEcCtD
Gliclazide—VEGFA—Oncostatin M Signaling Pathway—HRAS—head and neck cancer	0.000173	0.0034	CbGpPWpGaD
Gliclazide—Nervous system disorder—Docetaxel—head and neck cancer	0.000173	0.00181	CcSEcCtD
Gliclazide—CYP2C19—Cytochrome P450 - arranged by substrate type—CYP1A1—head and neck cancer	0.000173	0.0034	CbGpPWpGaD
Gliclazide—Pruritus—Fluorouracil—head and neck cancer	0.000173	0.00181	CcSEcCtD
Gliclazide—Thrombocytopenia—Docetaxel—head and neck cancer	0.000173	0.0018	CcSEcCtD
Gliclazide—Tachycardia—Docetaxel—head and neck cancer	0.000172	0.0018	CcSEcCtD
Gliclazide—Skin disorder—Docetaxel—head and neck cancer	0.000171	0.00179	CcSEcCtD
Gliclazide—CYP2C19—Oxidation by Cytochrome P450—CYP1A1—head and neck cancer	0.000171	0.00335	CbGpPWpGaD
Gliclazide—VEGFA—Cellular responses to stress—GPX1—head and neck cancer	0.000168	0.00331	CbGpPWpGaD
Gliclazide—Diarrhoea—Fluorouracil—head and neck cancer	0.000167	0.00175	CcSEcCtD
Gliclazide—Hypotension—Docetaxel—head and neck cancer	0.000165	0.00172	CcSEcCtD
Gliclazide—VEGFA—Integrated Breast Cancer Pathway—BCL2—head and neck cancer	0.000163	0.00321	CbGpPWpGaD
Gliclazide—Dizziness—Fluorouracil—head and neck cancer	0.000161	0.00169	CcSEcCtD
Gliclazide—Musculoskeletal discomfort—Docetaxel—head and neck cancer	0.000161	0.00168	CcSEcCtD
Gliclazide—Insomnia—Docetaxel—head and neck cancer	0.000159	0.00167	CcSEcCtD
Gliclazide—CYP2C19—Biological oxidations—NAT2—head and neck cancer	0.000159	0.00312	CbGpPWpGaD
Gliclazide—Paraesthesia—Docetaxel—head and neck cancer	0.000158	0.00165	CcSEcCtD
Gliclazide—VEGFA—Integrated Pancreatic Cancer Pathway—CASP8—head and neck cancer	0.000158	0.0031	CbGpPWpGaD
Gliclazide—CYP2C9—Cytochrome P450 - arranged by substrate type—CYP1A1—head and neck cancer	0.000158	0.0031	CbGpPWpGaD
Gliclazide—Dyspnoea—Docetaxel—head and neck cancer	0.000157	0.00164	CcSEcCtD
Gliclazide—VEGFA—Integrins in angiogenesis—AKT1—head and neck cancer	0.000157	0.00308	CbGpPWpGaD
Gliclazide—CYP2C19—Metapathway biotransformation—NAT2—head and neck cancer	0.000157	0.00308	CbGpPWpGaD
Gliclazide—Somnolence—Docetaxel—head and neck cancer	0.000157	0.00164	CcSEcCtD
Gliclazide—CYP2C9—Oxidation by Cytochrome P450—CYP1A1—head and neck cancer	0.000155	0.00306	CbGpPWpGaD
Gliclazide—Vomiting—Fluorouracil—head and neck cancer	0.000155	0.00162	CcSEcCtD
Gliclazide—Dyspepsia—Docetaxel—head and neck cancer	0.000155	0.00162	CcSEcCtD
Gliclazide—VEGFA—Endochondral Ossification—AKT1—head and neck cancer	0.000155	0.00304	CbGpPWpGaD
Gliclazide—Rash—Fluorouracil—head and neck cancer	0.000154	0.00161	CcSEcCtD
Gliclazide—Dermatitis—Fluorouracil—head and neck cancer	0.000154	0.00161	CcSEcCtD
Gliclazide—Headache—Fluorouracil—head and neck cancer	0.000153	0.0016	CcSEcCtD
Gliclazide—VEGFA—Oncostatin M Signaling Pathway—AKT1—head and neck cancer	0.000153	0.00301	CbGpPWpGaD
Gliclazide—VEGFA—VEGFA-VEGFR2 Pathway—MAPK3—head and neck cancer	0.000152	0.00299	CbGpPWpGaD
Gliclazide—Gastrointestinal disorder—Docetaxel—head and neck cancer	0.000152	0.00159	CcSEcCtD
Gliclazide—Fatigue—Docetaxel—head and neck cancer	0.000152	0.00159	CcSEcCtD
Gliclazide—VEGFA—HIF-1-alpha transcription factor network—AKT1—head and neck cancer	0.000151	0.00297	CbGpPWpGaD
Gliclazide—Pain—Docetaxel—head and neck cancer	0.000151	0.00158	CcSEcCtD
Gliclazide—Constipation—Docetaxel—head and neck cancer	0.000151	0.00158	CcSEcCtD
Gliclazide—ALB—Selenium Micronutrient Network—SOD2—head and neck cancer	0.00015	0.00295	CbGpPWpGaD
Gliclazide—VEGFA—Signaling events mediated by VEGFR1 and VEGFR2—AKT1—head and neck cancer	0.000148	0.0029	CbGpPWpGaD
Gliclazide—Feeling abnormal—Docetaxel—head and neck cancer	0.000145	0.00152	CcSEcCtD
Gliclazide—Nausea—Fluorouracil—head and neck cancer	0.000145	0.00152	CcSEcCtD
Gliclazide—CYP2C9—Biological oxidations—NAT2—head and neck cancer	0.000145	0.00285	CbGpPWpGaD
Gliclazide—VEGFA—VEGFA-VEGFR2 Pathway—MAPK1—head and neck cancer	0.000145	0.00285	CbGpPWpGaD
Gliclazide—Gastrointestinal pain—Docetaxel—head and neck cancer	0.000144	0.00151	CcSEcCtD
Gliclazide—VEGFA—Signaling by VEGF—MAPK3—head and neck cancer	0.000144	0.00282	CbGpPWpGaD
Gliclazide—ALB—Selenium Micronutrient Network—GPX1—head and neck cancer	0.000143	0.00281	CbGpPWpGaD
Gliclazide—CYP2C9—Metapathway biotransformation—NAT2—head and neck cancer	0.000143	0.00281	CbGpPWpGaD
Gliclazide—CYP2C19—Phase 1 - Functionalization of compounds—CYP1A1—head and neck cancer	0.00014	0.00275	CbGpPWpGaD
Gliclazide—VEGFA—Integrated Breast Cancer Pathway—CCND1—head and neck cancer	0.00014	0.00275	CbGpPWpGaD
Gliclazide—Body temperature increased—Docetaxel—head and neck cancer	0.000139	0.00146	CcSEcCtD
Gliclazide—Abdominal pain—Docetaxel—head and neck cancer	0.000139	0.00146	CcSEcCtD
Gliclazide—VEGFA—Signaling by VEGF—MAPK1—head and neck cancer	0.000137	0.00269	CbGpPWpGaD
Gliclazide—VEGFA—Focal Adhesion—BCL2—head and neck cancer	0.000136	0.00267	CbGpPWpGaD
Gliclazide—VEGFA—Integrated Pancreatic Cancer Pathway—BCL2—head and neck cancer	0.000135	0.00266	CbGpPWpGaD
Gliclazide—VEGFA—Integrated Breast Cancer Pathway—PTEN—head and neck cancer	0.000135	0.00266	CbGpPWpGaD
Gliclazide—Hypersensitivity—Docetaxel—head and neck cancer	0.00013	0.00136	CcSEcCtD
Gliclazide—VEGFA—EPH-Ephrin signaling—HRAS—head and neck cancer	0.000129	0.00253	CbGpPWpGaD
Gliclazide—VEGFA—Integrated Pancreatic Cancer Pathway—PTGS2—head and neck cancer	0.000128	0.00252	CbGpPWpGaD
Gliclazide—CYP2C9—Phase 1 - Functionalization of compounds—CYP1A1—head and neck cancer	0.000128	0.00251	CbGpPWpGaD
Gliclazide—Asthenia—Docetaxel—head and neck cancer	0.000126	0.00132	CcSEcCtD
Gliclazide—VEGFA—VEGFA-VEGFR2 Pathway—PIK3CA—head and neck cancer	0.000126	0.00247	CbGpPWpGaD
Gliclazide—Pruritus—Docetaxel—head and neck cancer	0.000125	0.0013	CcSEcCtD
Gliclazide—Diarrhoea—Docetaxel—head and neck cancer	0.000121	0.00126	CcSEcCtD
Gliclazide—CYP2C19—Arachidonic acid metabolism—PTGS2—head and neck cancer	0.000119	0.00234	CbGpPWpGaD
Gliclazide—VEGFA—Signaling by VEGF—PIK3CA—head and neck cancer	0.000119	0.00233	CbGpPWpGaD
Gliclazide—VEGFA—Focal Adhesion—CCND1—head and neck cancer	0.000117	0.00229	CbGpPWpGaD
Gliclazide—Dizziness—Docetaxel—head and neck cancer	0.000117	0.00122	CcSEcCtD
Gliclazide—VEGFA—VEGFA-VEGFR2 Pathway—HRAS—head and neck cancer	0.000116	0.00228	CbGpPWpGaD
Gliclazide—VEGFA—Integrated Pancreatic Cancer Pathway—CCND1—head and neck cancer	0.000116	0.00228	CbGpPWpGaD
Gliclazide—VEGFA—Focal Adhesion—PTEN—head and neck cancer	0.000112	0.00221	CbGpPWpGaD
Gliclazide—Vomiting—Docetaxel—head and neck cancer	0.000112	0.00117	CcSEcCtD
Gliclazide—VEGFA—Integrated Pancreatic Cancer Pathway—PTEN—head and neck cancer	0.000112	0.0022	CbGpPWpGaD
Gliclazide—Rash—Docetaxel—head and neck cancer	0.000111	0.00116	CcSEcCtD
Gliclazide—Dermatitis—Docetaxel—head and neck cancer	0.000111	0.00116	CcSEcCtD
Gliclazide—Headache—Docetaxel—head and neck cancer	0.00011	0.00115	CcSEcCtD
Gliclazide—VEGFA—Integrated Breast Cancer Pathway—MAPK1—head and neck cancer	0.00011	0.00216	CbGpPWpGaD
Gliclazide—VEGFA—Integrated Breast Cancer Pathway—EGFR—head and neck cancer	0.00011	0.00216	CbGpPWpGaD
Gliclazide—VEGFA—Signaling by VEGF—HRAS—head and neck cancer	0.00011	0.00216	CbGpPWpGaD
Gliclazide—CYP2C9—Arachidonic acid metabolism—PTGS2—head and neck cancer	0.000108	0.00213	CbGpPWpGaD
Gliclazide—VEGFA—Platelet activation, signaling and aggregation—IL2—head and neck cancer	0.000106	0.00208	CbGpPWpGaD
Gliclazide—Nausea—Docetaxel—head and neck cancer	0.000105	0.00109	CcSEcCtD
Gliclazide—VEGFA—VEGFA-VEGFR2 Pathway—AKT1—head and neck cancer	0.000103	0.00202	CbGpPWpGaD
Gliclazide—ALB—Folate Metabolism—IL2—head and neck cancer	9.83e-05	0.00193	CbGpPWpGaD
Gliclazide—VEGFA—Signaling by VEGF—AKT1—head and neck cancer	9.69e-05	0.0019	CbGpPWpGaD
Gliclazide—VEGFA—Integrated Pancreatic Cancer Pathway—MAPK3—head and neck cancer	9.57e-05	0.00188	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—NAT2—head and neck cancer	9.39e-05	0.00185	CbGpPWpGaD
Gliclazide—VEGFA—Integrated Breast Cancer Pathway—TP53—head and neck cancer	9.23e-05	0.00181	CbGpPWpGaD
Gliclazide—VEGFA—Focal Adhesion—MAPK1—head and neck cancer	9.15e-05	0.0018	CbGpPWpGaD
Gliclazide—VEGFA—Focal Adhesion—EGFR—head and neck cancer	9.14e-05	0.0018	CbGpPWpGaD
Gliclazide—VEGFA—Integrated Pancreatic Cancer Pathway—MAPK1—head and neck cancer	9.11e-05	0.00179	CbGpPWpGaD
Gliclazide—VEGFA—Integrated Pancreatic Cancer Pathway—EGFR—head and neck cancer	9.11e-05	0.00179	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—NAT2—head and neck cancer	9.11e-05	0.00179	CbGpPWpGaD
Gliclazide—VEGFA—Platelet activation, signaling and aggregation—MAPK3—head and neck cancer	8.52e-05	0.00167	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—KISS1—head and neck cancer	8.44e-05	0.00166	CbGpPWpGaD
Gliclazide—ALB—Selenium Micronutrient Network—PTGS2—head and neck cancer	8.43e-05	0.00166	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—DPYD—head and neck cancer	8.23e-05	0.00162	CbGpPWpGaD
Gliclazide—ALB—Transmembrane transport of small molecules—ATP7B—head and neck cancer	8.18e-05	0.00161	CbGpPWpGaD
Gliclazide—VEGFA—Platelet activation, signaling and aggregation—MAPK1—head and neck cancer	8.1e-05	0.00159	CbGpPWpGaD
Gliclazide—VEGFA—Developmental Biology—NOTCH1—head and neck cancer	8.09e-05	0.00159	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—DPYD—head and neck cancer	7.98e-05	0.00157	CbGpPWpGaD
Gliclazide—VEGFA—Focal Adhesion—PIK3CA—head and neck cancer	7.94e-05	0.00156	CbGpPWpGaD
Gliclazide—VEGFA—Integrated Pancreatic Cancer Pathway—PIK3CA—head and neck cancer	7.9e-05	0.00155	CbGpPWpGaD
Gliclazide—CYP2C19—Biological oxidations—GSTM1—head and neck cancer	7.85e-05	0.00154	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—YAP1—head and neck cancer	7.81e-05	0.00154	CbGpPWpGaD
Gliclazide—VEGFA—Integrated Breast Cancer Pathway—AKT1—head and neck cancer	7.79e-05	0.00153	CbGpPWpGaD
Gliclazide—CYP2C19—Metapathway biotransformation—GSTM1—head and neck cancer	7.74e-05	0.00152	CbGpPWpGaD
Gliclazide—VEGFA—Cellular responses to stress—STAT3—head and neck cancer	7.73e-05	0.00152	CbGpPWpGaD
Gliclazide—VEGFA—Integrated Pancreatic Cancer Pathway—TP53—head and neck cancer	7.65e-05	0.0015	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—YAP1—head and neck cancer	7.58e-05	0.00149	CbGpPWpGaD
Gliclazide—CYP2C19—Biological oxidations—CYP1A1—head and neck cancer	7.44e-05	0.00146	CbGpPWpGaD
Gliclazide—VEGFA—Cellular responses to stress—MAPK3—head and neck cancer	7.39e-05	0.00145	CbGpPWpGaD
Gliclazide—ALB—FOXA2 and FOXA3 transcription factor networks—AKT1—head and neck cancer	7.37e-05	0.00145	CbGpPWpGaD
Gliclazide—ABCC8—Neuronal System—MAPK1—head and neck cancer	7.36e-05	0.00145	CbGpPWpGaD
Gliclazide—VEGFA—Focal Adhesion—HRAS—head and neck cancer	7.34e-05	0.00144	CbGpPWpGaD
Gliclazide—CYP2C19—Metapathway biotransformation—CYP1A1—head and neck cancer	7.34e-05	0.00144	CbGpPWpGaD
Gliclazide—ALB—Metabolism—UROD—head and neck cancer	7.29e-05	0.00143	CbGpPWpGaD
Gliclazide—ALB—Platelet degranulation—VEGFA—head and neck cancer	7.16e-05	0.00141	CbGpPWpGaD
Gliclazide—CYP2C9—Biological oxidations—GSTM1—head and neck cancer	7.16e-05	0.00141	CbGpPWpGaD
Gliclazide—KCNJ11—Neuronal System—MAPK1—head and neck cancer	7.14e-05	0.0014	CbGpPWpGaD
Gliclazide—CYP2C9—Metapathway biotransformation—GSTM1—head and neck cancer	7.06e-05	0.00139	CbGpPWpGaD
Gliclazide—VEGFA—Platelet activation, signaling and aggregation—PIK3CA—head and neck cancer	7.03e-05	0.00138	CbGpPWpGaD
Gliclazide—VEGFA—Cellular responses to stress—MAPK1—head and neck cancer	7.03e-05	0.00138	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—GRP—head and neck cancer	6.95e-05	0.00137	CbGpPWpGaD
Gliclazide—ALB—Response to elevated platelet cytosolic Ca2+—VEGFA—head and neck cancer	6.82e-05	0.00134	CbGpPWpGaD
Gliclazide—CYP2C9—Biological oxidations—CYP1A1—head and neck cancer	6.79e-05	0.00133	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—STAT6—head and neck cancer	6.75e-05	0.00133	CbGpPWpGaD
Gliclazide—CYP2C9—Metapathway biotransformation—CYP1A1—head and neck cancer	6.69e-05	0.00132	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—UROD—head and neck cancer	6.55e-05	0.00129	CbGpPWpGaD
Gliclazide—VEGFA—Focal Adhesion—AKT1—head and neck cancer	6.48e-05	0.00127	CbGpPWpGaD
Gliclazide—VEGFA—Integrated Pancreatic Cancer Pathway—AKT1—head and neck cancer	6.46e-05	0.00127	CbGpPWpGaD
Gliclazide—ALB—Folate Metabolism—TP53—head and neck cancer	6.31e-05	0.00124	CbGpPWpGaD
Gliclazide—VEGFA—Axon guidance—MAPK3—head and neck cancer	6.27e-05	0.00123	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—YAP1—head and neck cancer	5.97e-05	0.00117	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—UROD—head and neck cancer	5.97e-05	0.00117	CbGpPWpGaD
Gliclazide—VEGFA—Axon guidance—MAPK1—head and neck cancer	5.97e-05	0.00117	CbGpPWpGaD
Gliclazide—VEGFA—Axon guidance—EGFR—head and neck cancer	5.97e-05	0.00117	CbGpPWpGaD
Gliclazide—ABCC8—Neuronal System—HRAS—head and neck cancer	5.91e-05	0.00116	CbGpPWpGaD
Gliclazide—VEGFA—Cellular responses to stress—TP53—head and neck cancer	5.9e-05	0.00116	CbGpPWpGaD
Gliclazide—VEGFA—Platelet activation, signaling and aggregation—AKT1—head and neck cancer	5.75e-05	0.00113	CbGpPWpGaD
Gliclazide—KCNJ11—Neuronal System—HRAS—head and neck cancer	5.73e-05	0.00113	CbGpPWpGaD
Gliclazide—ALB—Metabolism of lipids and lipoproteins—YAP1—head and neck cancer	5.66e-05	0.00111	CbGpPWpGaD
Gliclazide—VEGFA—Hemostasis—IL2—head and neck cancer	5.46e-05	0.00107	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism of lipids and lipoproteins—YAP1—head and neck cancer	5.08e-05	0.000998	CbGpPWpGaD
Gliclazide—VEGFA—Axon guidance—HRAS—head and neck cancer	4.79e-05	0.000941	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—TYMS—head and neck cancer	4.69e-05	0.000922	CbGpPWpGaD
Gliclazide—VEGFA—Developmental Biology—STAT3—head and neck cancer	4.68e-05	0.000921	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—GSTM1—head and neck cancer	4.64e-05	0.000911	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism of lipids and lipoproteins—YAP1—head and neck cancer	4.63e-05	0.00091	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—TYMS—head and neck cancer	4.55e-05	0.000894	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—GSTM1—head and neck cancer	4.5e-05	0.000884	CbGpPWpGaD
Gliclazide—VEGFA—Developmental Biology—MAPK3—head and neck cancer	4.48e-05	0.00088	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—GPX1—head and neck cancer	4.44e-05	0.000873	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—CYP1A1—head and neck cancer	4.4e-05	0.000864	CbGpPWpGaD
Gliclazide—VEGFA—Hemostasis—MAPK3—head and neck cancer	4.39e-05	0.000863	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—GPX1—head and neck cancer	4.31e-05	0.000846	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—CYP1A1—head and neck cancer	4.26e-05	0.000838	CbGpPWpGaD
Gliclazide—VEGFA—Developmental Biology—MAPK1—head and neck cancer	4.26e-05	0.000837	CbGpPWpGaD
Gliclazide—VEGFA—Developmental Biology—EGFR—head and neck cancer	4.26e-05	0.000837	CbGpPWpGaD
Gliclazide—VEGFA—Hemostasis—MAPK1—head and neck cancer	4.18e-05	0.000821	CbGpPWpGaD
Gliclazide—ALB—Platelet activation, signaling and aggregation—IL2—head and neck cancer	3.74e-05	0.000735	CbGpPWpGaD
Gliclazide—VEGFA—Hemostasis—PIK3CA—head and neck cancer	3.63e-05	0.000712	CbGpPWpGaD
Gliclazide—VEGFA—Hemostasis—TP53—head and neck cancer	3.51e-05	0.000689	CbGpPWpGaD
Gliclazide—VEGFA—Developmental Biology—HRAS—head and neck cancer	3.42e-05	0.000672	CbGpPWpGaD
Gliclazide—VEGFA—Hemostasis—HRAS—head and neck cancer	3.35e-05	0.000659	CbGpPWpGaD
Gliclazide—ALB—Metabolism of lipids and lipoproteins—GPX1—head and neck cancer	3.22e-05	0.000632	CbGpPWpGaD
Gliclazide—ALB—Metabolism of lipids and lipoproteins—CYP1A1—head and neck cancer	3.18e-05	0.000626	CbGpPWpGaD
Gliclazide—ALB—Platelet activation, signaling and aggregation—VEGFA—head and neck cancer	3.18e-05	0.000624	CbGpPWpGaD
Gliclazide—ALB—Metabolism—NAT2—head and neck cancer	3.03e-05	0.000595	CbGpPWpGaD
Gliclazide—VEGFA—Developmental Biology—AKT1—head and neck cancer	3.02e-05	0.000593	CbGpPWpGaD
Gliclazide—ALB—Platelet activation, signaling and aggregation—MAPK3—head and neck cancer	3.01e-05	0.000591	CbGpPWpGaD
Gliclazide—VEGFA—Hemostasis—AKT1—head and neck cancer	2.96e-05	0.000582	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism of lipids and lipoproteins—GPX1—head and neck cancer	2.89e-05	0.000567	CbGpPWpGaD
Gliclazide—ALB—Platelet activation, signaling and aggregation—MAPK1—head and neck cancer	2.86e-05	0.000562	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism of lipids and lipoproteins—CYP1A1—head and neck cancer	2.86e-05	0.000562	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—NAT2—head and neck cancer	2.72e-05	0.000534	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—NOTCH1—head and neck cancer	2.69e-05	0.000529	CbGpPWpGaD
Gliclazide—ALB—Metabolism—DPYD—head and neck cancer	2.66e-05	0.000522	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism of lipids and lipoproteins—GPX1—head and neck cancer	2.63e-05	0.000517	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—PTGS2—head and neck cancer	2.61e-05	0.000514	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism of lipids and lipoproteins—CYP1A1—head and neck cancer	2.61e-05	0.000512	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—PTGS2—head and neck cancer	2.54e-05	0.000498	CbGpPWpGaD
Gliclazide—ALB—Metabolism—YAP1—head and neck cancer	2.52e-05	0.000495	CbGpPWpGaD
Gliclazide—ALB—Platelet activation, signaling and aggregation—PIK3CA—head and neck cancer	2.48e-05	0.000488	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—NAT2—head and neck cancer	2.48e-05	0.000487	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—DPYD—head and neck cancer	2.38e-05	0.000468	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—PTEN—head and neck cancer	2.28e-05	0.000448	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—YAP1—head and neck cancer	2.26e-05	0.000444	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—PTEN—head and neck cancer	2.21e-05	0.000435	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—DPYD—head and neck cancer	2.17e-05	0.000427	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—YAP1—head and neck cancer	2.06e-05	0.000405	CbGpPWpGaD
Gliclazide—ALB—Platelet activation, signaling and aggregation—AKT1—head and neck cancer	2.03e-05	0.000398	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—IL2—head and neck cancer	1.93e-05	0.000379	CbGpPWpGaD
Gliclazide—ALB—Metabolism of lipids and lipoproteins—PTGS2—head and neck cancer	1.89e-05	0.000372	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—IL2—head and neck cancer	1.85e-05	0.000364	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—CCND1—head and neck cancer	1.8e-05	0.000355	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—PTEN—head and neck cancer	1.74e-05	0.000342	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism of lipids and lipoproteins—PTGS2—head and neck cancer	1.7e-05	0.000334	CbGpPWpGaD
Gliclazide—ALB—Metabolism of lipids and lipoproteins—PTEN—head and neck cancer	1.65e-05	0.000324	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—VEGFA—head and neck cancer	1.64e-05	0.000322	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—PIK3CA—head and neck cancer	1.61e-05	0.000316	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—PIK3CA—head and neck cancer	1.56e-05	0.000307	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—STAT3—head and neck cancer	1.56e-05	0.000306	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism of lipids and lipoproteins—PTGS2—head and neck cancer	1.55e-05	0.000305	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—MAPK3—head and neck cancer	1.55e-05	0.000304	CbGpPWpGaD
Gliclazide—ALB—Metabolism—TYMS—head and neck cancer	1.51e-05	0.000297	CbGpPWpGaD
Gliclazide—ALB—Metabolism—GSTM1—head and neck cancer	1.5e-05	0.000294	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—MAPK3—head and neck cancer	1.49e-05	0.000293	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism of lipids and lipoproteins—PTEN—head and neck cancer	1.48e-05	0.000291	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—MAPK1—head and neck cancer	1.47e-05	0.00029	CbGpPWpGaD
Gliclazide—ALB—Metabolism—GPX1—head and neck cancer	1.43e-05	0.000281	CbGpPWpGaD
Gliclazide—ALB—Metabolism—CYP1A1—head and neck cancer	1.42e-05	0.000279	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—MAPK1—head and neck cancer	1.42e-05	0.000278	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—EGFR—head and neck cancer	1.42e-05	0.000278	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—TYMS—head and neck cancer	1.36e-05	0.000267	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism of lipids and lipoproteins—PTEN—head and neck cancer	1.35e-05	0.000266	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—GSTM1—head and neck cancer	1.34e-05	0.000264	CbGpPWpGaD
Gliclazide—ABCC8—Metabolism—AKT1—head and neck cancer	1.31e-05	0.000258	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—GPX1—head and neck cancer	1.29e-05	0.000253	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—PIK3CA—head and neck cancer	1.28e-05	0.000251	CbGpPWpGaD
Gliclazide—KCNJ11—Metabolism—AKT1—head and neck cancer	1.27e-05	0.00025	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—CYP1A1—head and neck cancer	1.27e-05	0.00025	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—TYMS—head and neck cancer	1.24e-05	0.000243	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—TP53—head and neck cancer	1.24e-05	0.000243	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—PIK3CA—head and neck cancer	1.23e-05	0.000242	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—GSTM1—head and neck cancer	1.22e-05	0.000241	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—TP53—head and neck cancer	1.19e-05	0.000234	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—HRAS—head and neck cancer	1.18e-05	0.000233	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—GPX1—head and neck cancer	1.17e-05	0.00023	CbGpPWpGaD
Gliclazide—ALB—Metabolism of lipids and lipoproteins—PIK3CA—head and neck cancer	1.16e-05	0.000229	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—CYP1A1—head and neck cancer	1.16e-05	0.000228	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—HRAS—head and neck cancer	1.14e-05	0.000223	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism of lipids and lipoproteins—PIK3CA—head and neck cancer	1.05e-05	0.000205	CbGpPWpGaD
Gliclazide—ALB—Hemostasis—AKT1—head and neck cancer	1.05e-05	0.000205	CbGpPWpGaD
Gliclazide—VEGFA—Signaling Pathways—AKT1—head and neck cancer	1e-05	0.000197	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism of lipids and lipoproteins—PIK3CA—head and neck cancer	9.53e-06	0.000187	CbGpPWpGaD
Gliclazide—ALB—Metabolism—PTGS2—head and neck cancer	8.43e-06	0.000166	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—PTGS2—head and neck cancer	7.57e-06	0.000149	CbGpPWpGaD
Gliclazide—ALB—Metabolism—PTEN—head and neck cancer	7.35e-06	0.000144	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—PTGS2—head and neck cancer	6.9e-06	0.000136	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—PTEN—head and neck cancer	6.6e-06	0.00013	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—PTEN—head and neck cancer	6.02e-06	0.000118	CbGpPWpGaD
Gliclazide—ALB—Metabolism—PIK3CA—head and neck cancer	5.19e-06	0.000102	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—PIK3CA—head and neck cancer	4.66e-06	9.15e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—PIK3CA—head and neck cancer	4.25e-06	8.34e-05	CbGpPWpGaD
Gliclazide—ALB—Metabolism—AKT1—head and neck cancer	4.24e-06	8.33e-05	CbGpPWpGaD
Gliclazide—CYP2C19—Metabolism—AKT1—head and neck cancer	3.8e-06	7.47e-05	CbGpPWpGaD
Gliclazide—CYP2C9—Metabolism—AKT1—head and neck cancer	3.47e-06	6.82e-05	CbGpPWpGaD
